Kaleido Biosciences, Inc. KLDO
0.00 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.00001 52-week range 0.20005
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 4.26K
- Revenue (ttm)
- 855.00K
- EPS (ttm)
- -2.16
- Shares out
- 42.62M
- Forward P/E
- -0.06
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 1.05K
- Avg volume
- 935
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.00001 – 0.20005
- Beta
- -0.10
- Analysts
- Hold
- Price target
- 22.00 (+21999900.0%)
- Earnings date
- May 3, 2022
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- -32.01M
- PEG ratio
- 0.00
- Price / sales
- 2.49
- Price / book
- 0.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -78.40%
- Free cash flow
- -37.76M
- Total cash
- 55.66M
- Total debt
- 21.52M
- Return on equity
- -276.59%
- Short % of float
- 14.19%
- 50-day average
- 1.15
- 200-day average
- 3.55
Analyst view
Consensus: hold
Hold
Price target (mean) 22.00
Ratings (-1m) 6 4 buy · 0 hold · 2 sell
- Strong buy1
- Buy3
- Hold0
- Sell2
- Strong sell0
Next earnings
May 3, 2022
Expected May 3, 2022. Consensus EPS estimate -0.51.
Financials — quick view
KLDO Revenue — quarterly 492.00K
KLDO Net income — quarterly -20.27M
KLDO EPS — quarterly -0.48
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 3, 2022 | Mar 1, 2022 | -0.51 | — | — | — |
| Apr 6, 2022 | Dec 1, 2021 | -0.56 | — | — | — |
| Nov 1, 2021 | Sep 1, 2021 | -0.55 | — | — | — |
| Aug 11, 2021 | Jun 1, 2021 | -0.59 | — | — | — |
| May 4, 2021 | Mar 1, 2021 | -0.64 | — | — | — |
| Mar 3, 2021 | Dec 1, 2020 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 4, 2022 | Chardan Capital | down | Buy | Neutral |
| Jan 31, 2022 | Chardan Capital | main | — | Buy |
| Nov 12, 2021 | Chardan Capital | main | — | Buy |
| Nov 3, 2021 | JMP Securities | main | — | Market Outperform |
| Oct 19, 2021 | Morgan Stanley | down | Equal-Weight | Underweight |
| Mar 8, 2021 | Morgan Stanley | main | — | Equal-Weight |
About Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kaleido.com
News
Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL) 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR 
Dear KLDO Stock Fans, Mark Your Calendars for April 28 
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes 
Stocks That Hit 52-Week Lows On Friday 
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why 
ORIC Stock Plunges on Discontinuation of Oncology Candidate 
Stocks That Hit 52-Week Lows On Friday 
Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks
Your note
Sign in to keep a note on KLDO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONNEY MICHAEL W | Officer and Director | Conversion of Exercise of derivative security | Mar 3, 2019 | 0 |
| FLAGSHIP VENTURES FUND IV GENERAL PARTNER L L C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 7, 2021 | 0 |
| FLAGSHIP VENTURES FUND V GENERAL PARTNER L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 3, 2019 | 0 |
| MELAS-KYRIAZI THEO | Director | Purchase | Jun 3, 2020 | 33,333 |
| MENICHELLA DANIEL L. | Chief Executive Officer | Purchase | Feb 7, 2021 | 20,000 |
| QUINN ANTHONY G | Director | Conversion of Exercise of derivative security | Mar 3, 2019 | 31,603 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 45.93% | 19,575,710 | 46.79M | Dec 30, 2021 |
| FMR, LLC | 14.99% | 6,389,152 | 15.27M | Dec 30, 2021 |
| Harbourvest Partners, LLC | 4.30% | 1,833,832 | 4.38M | Dec 30, 2021 |
| Vanguard Group, Inc. (The) | 2.43% | 1,037,387 | 2.48M | Dec 30, 2021 |
| Blackrock Inc. | 2.17% | 923,831 | 2.21M | Dec 30, 2021 |
| Baillie Gifford and Company | 1.69% | 721,512 | 1.72M | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 5.41% | 2,303,879 | 3.43M | Feb 27, 2022 |
| Federated Hermes Kaufmann Fund | 1.39% | 591,140 | 1.04M | Jan 30, 2022 |
| Fidelity Growth Company K6 Fund | 1.36% | 579,169 | 862.96K | Feb 27, 2022 |
| Vanguard Total Stock Market Index Fund | 1.23% | 524,178 | 1.25M | Dec 30, 2021 |
| Fidelity Series Growth Company Fund | 1.16% | 493,648 | 735.53K | Feb 27, 2022 |
| iShares Russell 2000 ETF | 1.04% | 444,924 | 783.07K | Jan 30, 2022 |